China Vascular Grafts Market Growth & Trends
The China vascular grafts market size is expected to reach USD 172.8 million by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.6% from 2021 to 2028. The increasing prevalence of cardiovascular diseases, diabetes, and end-stage renal disease are the factors driving the market. The rise in the number of people suffering from these conditions is expected to boost the demand for these products in the coming years. In addition, the development of novel technologies, such as tissue-engineered materials, is expected to boost overall revenue over the forecast period. The COVD-19 pandemic has negatively impacted the country’s growth due to the increasing focus on COVID-19 treatment and recommended deferrals of elective medical procedures in the country.
In 2020, the endovascular stent-grafts product segment held the largest revenue share. The growth in the adoption of minimally invasive endovascular procedures due to their benefits such as short hospital stays low mortality rate, and perioperative morbidity, driving the segment growth. On the other hand, the peripheral vascular grafts segment is anticipated to be the fastest-growing segment during the forecast period owing to the increasing number of patients suffering from peripheral artery disease in China.
The cardiac aneurysm application segment accounted for the largest revenue share in 2020. The increasing prevalence of unruptured saccular aneurysms, affecting the flow of intracranial arteries, is expected to boost the adoption of these products over the forecast period. Abdominal Aortic Aneurysms (AAA) have a worse prognosis in men and have gained considerable attention in recent years, hence, gender-specific research about the development of novel products is expected to gain momentum over the forecast period. On the other hand, vascular occlusion application is expected to be the fastest-growing segment during the forecast period due to the increasing prevalence of vascular occlusive diseases and the easy availability of graft procedures. Technological advancements resulting in the development of novel therapies, which help to reduce the severity of acute ischemia after occlusion of PTFE grafts and thereby, minimizing the risks associated with prosthetic vascular grafts.
As of 2020, the polytetrafluoroethylene raw material segment accounted for the largest revenue share. It is anticipated to witness the fastest CAGR during the forecast period. Multiple applications of polytetrafluoroethylene vascular grafts, such as replacement of diseased arteries and creation of dialysis access site, along with many players offering a variety of polytetrafluoroethylene-based products are among factors supporting overall growth. In addition, easy availability of raw material and high tensile strength and durability are also responsible for high adoption in China.
China Vascular Grafts Market Report Highlights
- The market is expected to witness significant growth by 2028, owing to rising demand for minimally invasive procedures and the continuous introduction of innovative solutions
- The endovascular stent-grafts segment has dominated the market in 2020 due to increasing consumer preference for minimally invasive endovascular stent-grafts in China
- The cardiac aneurysm application segment dominated the market in 2020 due to the increasing prevalence of cardiovascular diseases in China
- The polytetrafluoroethylene raw material segment dominated the market in 2020 due to the rise in the number of players offering polytetrafluoroethylene vascular grafts
Please note The report will be delivered in 2-3 business days upon order notification.
- Chapter 1 Methodology and Scope
- 1.1 Market Segmentation and Scope
- 1.2 Research Methodology
- 1.2.1 Information Procurement
- 1.3 Information or Data Analysis
- 1.4 Research Scope and Assumptions
- 1.4.1 Methodology
- 1.4.1.1 Analysis Of The Company Market Share
- 1.4.1.2 Analysis Of Commodity Flow Model
- 1.5 Market Formulation & Validation
- 1.5.1 China Market: CAGR Calculation
- 1.5.2 China Segment Share Calculation
- 1.6 List to Data Sources
- Chapter 2 Executive Summary
- 2.1 Market Outlook
- 2.2 Segment Outlook
- 2.3 Competitive Insights
- Chapter 3 China Vascular Grafts Market Variables, Trends & Scope
- 3.1 Penetration and Growth Prospect Mapping
- 3.2 China Vascular Grafts Market Dynamics
- 3.2.1 Market Driver Analysis
- 3.2.2 Market Restraint Analysis
- 3.3 China Vascular Grafts Industry Analysis - Porter’s
- 3.3.1 Bargaining Power Of The Suppliers - Moderate
- 3.3.2 Bargaining Power Of The Buyers - Moderate
- 3.3.3 Threat Of Substitution - Low
- 3.3.4 Threats From New Entrants - Moderate
- 3.3.5 Competitive Rivalry - High
- 3.4 China Vascular Grafts Industry Analysis - PEST
- 3.4.1 Political Landscape
- 3.4.2 Economic Landscape
- 3.4.3 Social Landscape
- 3.4.4 Technology Landscape
- 3.5 Major Deals & Strategic Alliances Analysis
- 3.6 Impact of COVID-19 Pandemic on China Vascular Grafts Market
- Chapter 4 China Vascular Grafts Market: Competitive Analysis
- 4.1 Recent Developments & Impact Analysis, By Key Market Participants
- 4.1.1 Partnerships And Collaborations
- 4.1.1.1 Cook Medical And Bentley
- 4.1.1.2 Lombard Medical And Microport Scientific Corporation
- 4.1.2 Mergers And Acquistions
- 4.1.2.1 Lemaitre Vascular, Inc. And Artegraft, Inc.
- 4.1.2.2 Tva Medical, Inc. Acquired By Bd
- 4.1.2.3 Microport Scientific And Lombard Medical
- 4.1.2.4 Bd And C. R. Bard, Inc.
- 4.1.3 Product Approvals
- 4.1.3.1 China National Medical Products Administration (NMPA) Approved Minos Abdominal Aortic Stent Graft And Delivery System
- 4.1.3.2 Biotyx Medical’s Ibs Angel Approved By NMPA
- 4.1.3.3 Artery Stent Graft System Approval By NMPA
- 4.1.3.4 Lifetech Scientific Corporation Obtained Registration Approval From NMPA
- 4.1.3.5 Microport Endovascular (Shanghai) Co., Ltd. Announced Regulatory Approval Of Castor By China CFDA
- 4.2 Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
- 4.3 Vendor Landscape
- 4.3.1 List Of Key Distributors/Channel Partners
- 4.3.2 Key Customers
- 4.3.3 Company Sales Value, 2016 To 2020, Usd Million
- 4.3.4 Key Customers List Of Key Emerging Companies/Technology Disruptors/ Innovators
- 4.3.5 Company Market Position Analysis (Geographical Presence, Product Portfolio, Key Alliance, Industry Experience)
- Chapter 5 China Vascular Grafts Market: Product Market Estimates & Trend Analysis
- 5.1 China Vascular Grafts Market: Product Analysis
- 5.1.1 Hemodialysis Access Grafts
- 5.1.1.1 China hemodialysis access grafts market value estimates and forecasts, 2016 - 2028 (USD Million)
- 5.1.2 Endovascular Stent Grafts
- 5.1.2.1 China endovascular stent grafts market value estimates and forecasts, 2016 - 2028 (USD Million)
- 5.1.3 Coronary Artery By-Pass Grafts
- 5.1.3.1 China coronary artery by-pass grafts market value estimates and forecasts, 2016 - 2028 (USD Million)
- 5.1.4 Vascular Grafts For Aorta Disease
- 5.1.4.1 China vascular grafts for aorta disease market value estimates and forecasts, 2016 - 2028 (USD Million)
- 5.1.5 Peripheral Vascular Grafts
- 5.1.5.1 China peripheral vascular grafts market value estimates and forecasts, 2016 - 2028 (USD Million)
- Chapter 6 China Vascular Grafts Market: Application Estimates & Trend Analysis
- 6.1 China Vascular Grafts Market: Application Movement Analysis
- 6.1.1 Cardiac Aneurysm
- 6.1.1.1 China cardiac aneurysm market estimates and forecasts, 2016 - 2028 (usd mUSD Million)
- 6.1.1.2 Endovascular Stent Graft
- 6.1.1.2.1 China endovascular stent graft market estimates and forecasts, 2016 - 2028 (USD Million)
- 6.1.1.3 Vascular Graft In Cardiac Aneurysm
- 6.1.1.3.1 China vascular graft in cardiac aneurysm market estimates and forecasts, 2016 - 2028 (USD Million)
- 6.1.2 Kidney Failure
- 6.1.2.1 China kidney failure market estimates and forecasts, 2016 - 2028 (USD Million)
- 6.1.3 Vascular Occlusion
- 6.1.3.1 China vascular occlusion market estimates and forecasts, 2016 - 2028 (USD Million)
- 6.1.4 Coronary Artery Disease
- 6.1.4.1 China coronary artery disease market estimates and forecasts, 2016 - 2028 (USD Million)
- Chapter 7 China Vascular Grafts Market: Raw Material Estimates & Trend Analysis
- 7.1 China Vascular Grafts Market: Raw Material Movement Analysis
- 7.1.1 Polyester Vascular Grafts
- 7.1.1.1 China polyester vascular grafts market estimates and forecasts, 2016 - 2028 (USD Million)
- 7.1.2 Polytetrafluoroethylene Vascular Grafts
- 7.1.2.1 China polytetrafluoroethylene vascular grafts market estimates and forecasts, 2016 - 2028 (USD Million)
- 7.1.3 Polyurethane Vascular Grafts
- 7.1.3.1 china polyurethane vascular grafts market estimates and forecasts, 2016 - 2028 (USD Million)
- 7.1.4 Biological Material Based Vascular Grafts
- 7.1.4.1 China biological material based vascular grafts market estimates and forecasts, 2016 - 2028 (USD Million)
- 7.1.4.2 Human Saphenous and Umbilical Veins
- 7.1.4.2.1 China human saphenous and umbilical veins market estimates and forecasts, 2016 - 2028 (USD Million)
- 7.1.4.3 Tissue Engineered Materials
- 7.1.4.3.1 China tissue engineered materials market estimates and forecasts, 2016 - 2028 (USD Million)
- Chapter 8 Competitive Landscape
- 8.1 Company Profiles
- 8.1.1 Medtronic plc
- 8.1.1.1 Company Overview
- 8.1.1.2 Financial Performance
- 8.1.1.3 Product Benchmarking
- 8.1.1.4 Strategic initiatives
- 8.1.2 Terumo Corporation
- 8.1.2.1 Company Overview
- 8.1.2.2 Financial Performance
- 8.1.2.3 Product Benchmarking
- 8.1.2.4 Strategic Initiatives
- 8.1.3 LeMaitre Vascular, Inc.
- 8.1.3.1 Company Overview
- 8.1.3.2 Financial Performance
- 8.1.3.3 Product Benchmarking
- 8.1.3.4 Strategic Initiatives
- 8.1.4 C.R. Bard; W.L. Gore and Associates, Inc.
- 8.1.4.1 Company Overview
- 8.1.4.2 Financial Performance
- 8.1.4.3 Product Benchmarking
- 8.1.4.4 Strategic Initiatives
- 8.1.5 Cook
- 8.1.5.1 Company Overview
- 8.1.5.2 Financial Performance
- 8.1.5.3 Product Benchmarking
- 8.1.5.4 Strategic Initiaves
- 8.1.6 Shanghai Suokang Medical Implants Co. Ltd.
- 8.1.6.1 Company Overview
- 8.1.6.2 Financial Performance
- 8.1.6.3 Product Benchmarking
- 8.1.6.4 Strategic Initiaves
- 8.1.7 Getinge AB
- 8.1.7.1 Company Overview
- 8.1.7.2 Financial Performance
- 8.1.7.3 Product Benchmarking
- 8.1.7.4 Strategic Initiatives